Alternative Data for Kymera Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 20,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 837 | Sign up | Sign up | Sign up |
| X Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
| Price | $84.58 |
| Target Price | Sign up |
| Volume | 438,176 |
| Market Cap | $6.82B |
| Year Range | $37.68 - $95.03 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation RisesFebruary 20 - SeekingAlpha |
|
 |
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 13 - SeekingAlpha |
|
Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 12 - SeekingAlpha |
 |
Earnings Scheduled For February 26, 2026February 25 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 2.8M | 74M | -71M | -82M | -79M | -0.940 |
| Q2 '25 | 11M | 2.1M | 9.4M | -77M | -74M | -0.950 |
| Q1 '25 | 22M | 2M | 22M | -66M | -63M | -0.820 |
| Q4 '24 | 7.4M | 2M | 7.4M | -71M | -69M | -0.890 |
| Q3 '24 | 3.7M | 2M | 3.7M | -62M | -60M | -0.820 |
Insider Transactions View All
| Jacobs Bruce N. filed to sell 232,588 shares at $86.6. March 4 '26 |
| Jacobs Bruce N. filed to sell 236,991 shares at $84. March 4 '26 |
| Gollob Jared filed to sell 117,134 shares at $86.6. March 4 '26 |
| Gollob Jared filed to sell 121,537 shares at $84. March 4 '26 |
| Chadwick Jeremy G filed to sell 73,810 shares at $86.6. March 4 '26 |
Similar companies
Read more about Kymera Therapeutics (KYMR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Kymera Therapeutics
The Market Cap of Kymera Therapeutics is $6.82B.
Currently, the price of one share of Kymera Therapeutics stock is $84.58.
The KYMR stock price chart above provides a comprehensive visual representation of Kymera Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Kymera Therapeutics shares. Our platform offers an up-to-date KYMR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Kymera Therapeutics (KYMR) does not offer dividends to its shareholders. Investors interested in Kymera Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Kymera Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
